Protagonist Therapeutics (PTGX) Tops Q1 EPS by 207c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $3.26, $2.07 better than the analyst estimate of $1.19. Revenue for the quarter came in at $254.95 million versus the consensus estimate of $120 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Halozyme prices $1.3B convertible notes offering due 2033
• Goldman sees India AI infrastructure stocks up 60% in 2026